Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
3.48
Dollar change
-0.19
Percentage change
-5.18
%
Index- P/E- EPS (ttm)-0.07 Insider Own40.77% Shs Outstand74.98M Perf Week8.75%
Market Cap262.08M Forward P/E60.52 EPS next Y0.06 Insider Trans0.02% Shs Float44.60M Perf Month102.33%
Income-4.94M PEG- EPS next Q-0.02 Inst Own15.50% Short Float2.63% Perf Quarter140.00%
Sales83.57M P/S3.14 EPS this Y78.57% Inst Trans-19.26% Short Ratio5.48 Perf Half Y140.00%
Book/sh0.38 P/B9.17 EPS next Y483.33% ROA-9.06% Short Interest1.17M Perf Year124.52%
Cash/sh0.36 P/C9.59 EPS next 5Y- ROE-17.29% 52W Range1.25 - 4.06 Perf YTD143.36%
Dividend Est.- P/FCF38.04 EPS past 5Y35.83% ROI-15.91% 52W High-14.28% Beta1.99
Dividend TTM- Quick Ratio1.70 Sales past 5Y22.27% Gross Margin60.76% 52W Low178.40% ATR (14)0.35
Dividend Ex-Date- Current Ratio2.40 EPS Y/Y TTM72.60% Oper. Margin-3.95% RSI (14)71.71 Volatility16.03% 13.97%
Employees106 Debt/Eq0.12 Sales Y/Y TTM15.99% Profit Margin-5.91% Recom1.00 Target Price5.91
Option/ShortYes / Yes LT Debt/Eq0.09 EPS Q/Q107.81% Payout- Rel Volume2.27 Prev Close3.67
Sales Surprise1.84% EPS Surprise100.00% Sales Q/Q0.95% EarningsMar 06 AMC Avg Volume214.23K Price3.48
SMA2042.62% SMA5083.64% SMA200118.46% Trades Volume486,389 Change-5.18%
Date Action Analyst Rating Change Price Target Change
Aug-16-22Downgrade Oppenheimer Outperform → Perform
Aug-11-22Downgrade B. Riley Securities Buy → Neutral $6 → $2.40
Mar-08-22Initiated ROTH Capital Buy $7
Oct-16-19Initiated Oppenheimer Outperform $6
Feb-14-19Initiated B. Riley FBR Buy $7
Nov-27-17Resumed H.C. Wainwright Buy $6 → $8
Sep-25-17Initiated Ladenburg Thalmann Buy $7
Jan-03-17Initiated Rodman & Renshaw Buy $6
Mar-26-24 08:32AM
Mar-07-24 01:59PM
10:37AM
06:27AM
Mar-06-24 09:53PM
04:04PM Loading…
04:04PM
Feb-21-24 08:32AM
Feb-05-24 08:32AM
Jan-26-24 04:08PM
Dec-20-23 09:04AM
Dec-12-23 10:30AM
Nov-30-23 08:34AM
Nov-15-23 08:32AM
Nov-10-23 12:54PM
Nov-09-23 08:32AM
06:33PM Loading…
Nov-08-23 06:33PM
04:48PM
04:02PM
Nov-01-23 08:34AM
Oct-31-23 08:34AM
Oct-26-23 08:32AM
Oct-02-23 08:32AM
Aug-24-23 08:32AM
Aug-12-23 09:04AM
Aug-10-23 10:38AM
Aug-09-23 05:40PM
04:37PM
04:02PM
Aug-08-23 08:34AM
Aug-07-23 08:32AM
08:02AM Loading…
Aug-02-23 08:02AM
Jul-18-23 08:32AM
Jun-16-23 08:32AM
Jun-08-23 08:19AM
May-30-23 08:34AM
May-11-23 08:34AM
May-10-23 05:35PM
04:32PM
04:02PM
May-02-23 08:32AM
06:31AM
Apr-12-23 01:04PM
Mar-27-23 06:43AM
Mar-10-23 05:23AM
02:28AM
Mar-09-23 09:06AM
Mar-08-23 06:25PM
04:02PM
Mar-06-23 08:34AM
Mar-02-23 10:00AM
Mar-01-23 10:00AM
Feb-27-23 08:32AM
Feb-22-23 08:34AM
Feb-21-23 08:32AM
Jan-31-23 08:32AM
Jan-17-23 08:28AM
Jan-15-23 08:52AM
Jan-12-23 08:34AM
Jan-05-23 08:33AM
Dec-27-22 08:30AM
Dec-19-22 09:35AM
Dec-16-22 09:35AM
Nov-11-22 08:12AM
Nov-09-22 05:02AM
Nov-02-22 05:35PM
04:02PM
11:40AM
Oct-26-22 08:35AM
Oct-24-22 08:32AM
Oct-11-22 07:32AM
Oct-06-22 08:53AM
Oct-04-22 06:32AM
Oct-03-22 07:30AM
Sep-19-22 06:05PM
Sep-01-22 06:32AM
Aug-29-22 03:07PM
Aug-24-22 09:00AM
09:00AM
Aug-15-22 06:34AM
Aug-10-22 05:45PM
04:02PM
Aug-08-22 09:41AM
Aug-02-22 06:32AM
Jul-10-22 09:57AM
Jul-07-22 06:32AM
Jun-22-22 06:07AM
Jun-15-22 06:34AM
Jun-10-22 06:32AM
Jun-07-22 01:33PM
Jun-02-22 06:34AM
Jun-01-22 06:32AM
May-22-22 08:17AM
May-20-22 10:02AM
May-19-22 04:34PM
May-17-22 08:27AM
06:34AM
May-12-22 05:35PM
04:03PM
May-09-22 08:25AM
May-05-22 08:35PM
Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm's proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gerber BriannaChief Financial OfficerDec 01 '23Buy1.415,0007,05027,436Dec 04 04:12 PM
Jaksch Frank L JrDirectorJun 12 '23Buy1.697,00011,830231,339Jun 13 04:50 PM
Fried Robert NChief Executive OfficerMay 31 '23Buy1.427,0009,94095,001Jun 01 04:27 PM
Rubin Steven DDirectorMay 25 '23Buy1.467,00010,2207,000May 30 04:13 PM
Last Close
Mar 28 04:00PM ET
100.12
Dollar change
+1.04
Percentage change
1.05
%
PII Polaris Inc daily Stock Chart
Index- P/E11.50 EPS (ttm)8.71 Insider Own6.27% Shs Outstand56.50M Perf Week5.70%
Market Cap5.65B Forward P/E10.87 EPS next Y9.21 Insider Trans0.00% Shs Float52.86M Perf Month7.82%
Income502.80M PEG0.77 EPS next Q0.04 Inst Own85.82% Short Float6.54% Perf Quarter3.98%
Sales8.93B P/S0.63 EPS this Y-13.45% Inst Trans-6.28% Short Ratio4.98 Perf Half Y-1.56%
Book/sh25.10 P/B3.99 EPS next Y16.18% ROA9.37% Short Interest3.46M Perf Year-6.47%
Cash/sh6.52 P/C15.35 EPS next 5Y15.00% ROE39.95% 52W Range82.00 - 138.49 Perf YTD5.65%
Dividend Est.2.65 (2.65%) P/FCF10.26 EPS past 5Y10.70% ROI14.84% 52W High-27.71% Beta1.60
Dividend TTM2.61 (2.61%) Quick Ratio0.46 Sales past 5Y8.11% Gross Margin21.33% 52W Low22.10% ATR (14)2.38
Dividend Ex-DateFeb 29, 2024 Current Ratio1.39 EPS Y/Y TTM-11.88% Oper. Margin7.02% RSI (14)69.83 Volatility2.50% 2.40%
Employees18500 Debt/Eq1.45 Sales Y/Y TTM1.94% Profit Margin5.63% Recom2.56 Target Price98.15
Option/ShortYes / Yes LT Debt/Eq1.39 EPS Q/Q-45.85% Payout29.84% Rel Volume0.85 Prev Close99.08
Sales Surprise2.01% EPS Surprise-22.62% Sales Q/Q-4.78% EarningsJan 30 BMO Avg Volume693.56K Price100.12
SMA207.76% SMA508.72% SMA200-1.96% Trades Volume592,953 Change1.05%
Date Action Analyst Rating Change Price Target Change
Jan-17-24Upgrade Morgan Stanley Equal-Weight → Overweight $103 → $113
Sep-27-23Resumed Morgan Stanley Equal-Weight $120
Jul-18-23Downgrade Raymond James Strong Buy → Mkt Perform
Apr-19-23Initiated KeyBanc Capital Markets Overweight $125
Jan-27-23Downgrade UBS Buy → Neutral $165 → $112
Jan-13-23Downgrade Northcoast Buy → Neutral
Dec-08-22Downgrade BMO Capital Markets Outperform → Market Perform $120 → $110
Nov-30-22Initiated MKM Partners Neutral $117
Oct-19-22Downgrade Citigroup Buy → Neutral $131 → $101
Jun-28-22Initiated Jefferies Hold $105
Mar-25-24 05:44PM
07:00AM
Mar-20-24 12:00PM
Mar-07-24 05:40PM
09:05AM
07:00AM Loading…
Mar-05-24 07:00AM
Mar-04-24 11:58AM
Mar-01-24 08:52AM
Feb-28-24 04:32PM
Feb-20-24 12:00PM
Feb-16-24 03:51AM
Feb-13-24 10:01AM
Feb-09-24 11:36AM
Feb-06-24 12:00PM
Feb-04-24 06:54PM
04:15PM Loading…
Feb-01-24 04:15PM
10:33AM
Jan-30-24 02:13PM
02:01PM
10:45AM
09:30AM
07:10AM
06:00AM
Jan-29-24 05:45PM
Jan-23-24 10:00AM
Jan-19-24 02:55PM
Jan-12-24 11:45PM
Jan-11-24 07:00AM
Jan-04-24 03:27PM
Dec-27-23 12:00PM
07:00AM Loading…
07:00AM
Dec-14-23 03:07PM
Dec-08-23 10:23AM
Dec-05-23 11:01AM
Dec-01-23 08:03AM
Nov-25-23 07:30AM
Nov-20-23 08:27PM
Nov-16-23 10:37AM
Nov-15-23 09:30AM
Nov-09-23 04:15PM
Nov-07-23 12:01PM
Oct-31-23 06:30AM
Oct-26-23 04:15PM
08:07AM
Oct-25-23 12:59PM
Oct-24-23 09:37AM
09:35AM
06:00AM
Oct-23-23 12:02PM
Oct-17-23 10:00AM
Oct-05-23 07:00PM
Sep-27-23 06:00AM
Sep-19-23 10:00AM
Sep-13-23 09:40AM
Sep-11-23 05:07PM
Sep-05-23 04:48PM
Aug-28-23 02:00PM
11:30AM
11:00AM
Aug-23-23 02:02PM
Aug-22-23 05:45PM
Aug-21-23 09:40AM
Aug-15-23 01:46PM
Aug-10-23 11:00AM
Aug-09-23 01:54PM
Jul-31-23 07:15AM
07:02AM
Jul-27-23 04:15PM
Jul-26-23 12:14PM
11:00AM
Jul-25-23 12:18PM
06:00AM
Jul-12-23 09:02AM
Jul-11-23 11:00AM
Jul-04-23 07:00AM
Jun-27-23 01:31PM
07:00AM
Jun-22-23 12:25PM
Jun-21-23 08:00PM
Jun-09-23 07:59AM
Jun-07-23 01:00PM
Jun-05-23 01:38PM
Jun-01-23 07:00AM
May-30-23 12:00PM
May-26-23 06:37AM
May-22-23 06:11AM
May-18-23 10:00AM
May-17-23 11:05AM
May-16-23 12:00PM
May-15-23 06:40AM
May-01-23 06:12AM
Apr-28-23 12:55PM
Apr-27-23 04:15PM
Apr-26-23 08:00PM
Apr-25-23 06:00AM
Apr-24-23 03:07PM
Apr-21-23 12:19PM
Apr-20-23 11:45AM
Apr-19-23 12:05PM
Apr-18-23 10:01AM
Polaris Inc. engages in designing, engineering, and manufacturing power sports vehicles. It operates through the following segments: Off-Road, On-Road, and Marine. The Off-Road segment includes off-road vehicles (ORV) and snowmobiles. The On Road segment is involved in the design and manufacture of motorcycles, motorbikes, light duty hauling, and passenger vehicles. The Marine segment focuses on the design and manufacture of boats. The company was founded by Edgar E. Hetteen, Allan Hetten, and David Johnson in 1954 and is headquartered in Medina, MN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mack Robert PaulCFO, EVP - Finance + Corp DevAug 07 '23Option Exercise84.588,312703,02936,668Aug 08 05:25 PM
Mack Robert PaulCFO, EVP - Finance + Corp DevAug 07 '23Sale130.008,3121,080,56028,356Aug 08 05:25 PM
FARR KEVIN MDirectorAug 03 '23Sale133.283,225429,82814,645Aug 07 05:03 PM
Eastman Stephen L.President - PG&A + AftermarketJul 28 '23Option Exercise125.6710,0001,256,70027,800Aug 01 06:20 PM
Duke Benjamin DPresident-MarineJul 28 '23Option Exercise105.631,454153,5835,969Aug 01 06:19 PM
Eastman Stephen L.President - PG&A + AftermarketJul 28 '23Sale135.8210,0001,358,20017,800Aug 01 06:20 PM
Speetzen Michael TCEOJul 28 '23Sale135.812,540344,95753,527Jul 31 09:38 PM
Clark Dougherty LucySVP-Gen Counsel & SecretaryJul 27 '23Option Exercise114.1938,8874,440,47957,301Jul 31 09:48 PM
Speetzen Michael TCEOJul 27 '23Option Exercise84.5845,9323,884,929101,999Jul 31 09:38 PM
Dougherty Michael D.President - On Road and Int'lJul 27 '23Option Exercise100.1421,1242,115,38843,515Jul 31 09:37 PM
Speetzen Michael TCEOJul 27 '23Sale136.1458,3017,937,13156,067Jul 31 09:38 PM
Clark Dougherty LucySVP-Gen Counsel & SecretaryJul 27 '23Sale134.6738,8875,237,01818,414Jul 31 09:48 PM
Dougherty Michael D.President - On Road and Int'lJul 27 '23Sale135.9921,1242,872,69422,391Jul 31 09:37 PM
FARR KEVIN MDirectorJul 27 '23Sale134.331,615216,94317,870Jul 31 09:33 PM
Williams James PSVP-CHROJul 12 '23Option Exercise125.6714,0001,759,38030,001Jul 13 07:38 PM
Williams James PSVP-CHROJul 12 '23Sale130.0014,0001,820,00016,001Jul 13 07:38 PM